Voices
Hope Rugo
Hope Rugo/ucsfhealth.org

Hope Rugo: New Findings on Trastuzumab Deruxtecan Retreatment Post-ILD Recovery

Hope Rugo, Professor of Medicine at the University of California San Francisco, shared a post on X:

“Excited to see our new publication! Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 ILD/pneumonitis in Annals of Oncology. Marked efficacy with reRx post recovery!”

Title: Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis

Authors: H.S. Rugo, E. Tokunaga, H. Iwata, V. Petry, E.F. Smit, Y. Goto, D.-W. Kim, K. Shitara, J.F. Gruden, S. Modi, J. Cortés, I. Krop, P.A. Jänne, Y. Cheng, C. Taitt, F.-C. Cheng, C.A. Powell

Read Full Article.

Trastuzumab Deruxtecan

More posts featuring Hope Rugo on OncoDaily.

C. Taitt C.A. Powell cancer D. W. Kim E. Tokunaga E.F. Smit F.-C. Cheng H S Rugo H. Iwata Headlines Hope Rugo I. Krop J. Cortes J.F. Gruden K. Shitara OncoDaily Oncology P.A. Janne S Modi V. Petry Y. Cheng Y. Goto